Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1995 1
1999 1
2002 1
2003 3
2004 1
2005 2
2006 1
2007 2
2008 4
2009 3
2018 2
2020 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
UFT (tegafur-uracil) in rectal cancer.
Casado E, Pfeiffer P, Feliu J, González-Barón M, Vestermark L, Jensen HA. Casado E, et al. Ann Oncol. 2008 Aug;19(8):1371-1378. doi: 10.1093/annonc/mdn067. Epub 2008 Apr 1. Ann Oncol. 2008. PMID: 18381370 Free article. Review.
However, CI 5-FU is inconvenient for patients and is costly. Oral fluoropyrimidines like UFT (tegafur-uracil) offer a number of advantages over 5-FU. METHODS: We undertook a review of published articles and abstracts relating to clinical studies of UFT in the …
However, CI 5-FU is inconvenient for patients and is costly. Oral fluoropyrimidines like UFT (tegafur-uracil) offer a n …
The role of UFT in metastatic colorectal cancer.
Bennouna J, Saunders M, Douillard JY. Bennouna J, et al. Oncology. 2009;76(5):301-10. doi: 10.1159/000209334. Epub 2009 Mar 20. Oncology. 2009. PMID: 19299903 Review.
5-Fluorouracil (5-FU) has been the most widely used chemotherapeutic agent for metastatic colorectal cancer (mCRC) and 5-FU combination therapy improves efficacy compared with monotherapy. The oral fluoropyrimidine UFT (tegafur-uracil) with leucovorin (LV) im …
5-Fluorouracil (5-FU) has been the most widely used chemotherapeutic agent for metastatic colorectal cancer (mCRC) and 5-FU combination ther …
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer.
Miyoshi T, Kondo K, Toba H, Yoshida M, Fujino H, Kenzaki K, Sakiyama S, Takehisa M, Tangoku A. Miyoshi T, et al. Anticancer Res. 2007 Jul-Aug;27(4C):2641-8. Anticancer Res. 2007. PMID: 17695427 Free article.
BACKGROUND: UFT (tegafur + uracil) has been reported to be effective as an adjuvant in postoperative chemotherapy for non-small cell lung cancer (NSCLC) in a randomized prospective study. ...
BACKGROUND: UFT (tegafur + uracil) has been reported to be effective as an adjuvant in postoperative chemotherapy for n …
The role of UFT in advanced gastric cancer.
Aykan NF, Idelevich E. Aykan NF, et al. Ann Oncol. 2008 Jun;19(6):1045-52. doi: 10.1093/annonc/mdn024. Epub 2008 Feb 14. Ann Oncol. 2008. PMID: 18281263 Free article. Review.
Combination chemotherapy, however, is associated with a significant survival benefit compared with monotherapy and i.v. 5-fluorouracil (5-FU) is one of the most widely used agents. UFT (tegafur-uracil) has similar efficacy to continuous infusion 5-FU with imp …
Combination chemotherapy, however, is associated with a significant survival benefit compared with monotherapy and i.v. 5-fluorouracil (5-FU …
A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Mackay HJ, Hill M, Twelves C, Glasspool R, Price T, Campbell S, Massey A, Macham MA, Uzzel M, Bailey SM, Martin C, Cunningham D. Mackay HJ, et al. Ann Oncol. 2003 Aug;14(8):1264-9. doi: 10.1093/annonc/mdg340. Ann Oncol. 2003. PMID: 12881390 Free article. Clinical Trial.
BACKGROUND: The aim of this study was to determine the maximum tolerated dose (MTD), toxicity profile and response rate of the oral 5-fluorouracil prodrug UFT (tegafur/uracil) and leucovorin (LV) in combination with irinotecan in patients with advanced or met …
BACKGROUND: The aim of this study was to determine the maximum tolerated dose (MTD), toxicity profile and response rate of the oral 5-fluoro …
Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC).
Nakayama T, Sagara Y, Takashima T, Matsunami N, Masuda N, Miyoshi Y, Taguchi T, Aono T, Ito T, Kagimura T, Noguchi S. Nakayama T, et al. Cancer Chemother Pharmacol. 2018 Apr;81(4):755-762. doi: 10.1007/s00280-018-3544-5. Epub 2018 Feb 21. Cancer Chemother Pharmacol. 2018. PMID: 29468454 Free PMC article. Clinical Trial.
Patients were randomized 1:1 by minimization to orally receive either anastrozole (1 mg once daily) plus UFT (tegafur/uracil combination in 1:4 molar ratio; 270 mg/m(2)/day in two divided doses) or anastrozole (as above) alone for 24 weeks. ...
Patients were randomized 1:1 by minimization to orally receive either anastrozole (1 mg once daily) plus UFT (tegafur/uraci …
Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
Nakagawa T, Tanaka F, Takata T, Matsuoka K, Miyahara R, Otake Y, Yanagihara K, Fukushimab M, Wada H. Nakagawa T, et al. J Surg Oncol. 2002 Oct;81(2):87-92. doi: 10.1002/jso.10137. J Surg Oncol. 2002. PMID: 12355409
In the present study, we analyzed DPD expression in tumors and investigated retrospectively the relationship between the efficacy of UFT (Tegafur + Uracil) as adjuvant chemotherapy and DPD expression in nonsmall-cell lung cancer (NSCLC). ...
In the present study, we analyzed DPD expression in tumors and investigated retrospectively the relationship between the efficacy of UFT …
Clinical T2N0 Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy plus Local Excision.
Suzuki T, Sadahiro S, Okada K, Miyakita H, Ogimi T, Chan LF, Kamei Y, Yamamoto S. Suzuki T, et al. Oncology. 2023;101(3):166-172. doi: 10.1159/000527137. Epub 2022 Oct 28. Oncology. 2023. PMID: 36310019
Chemoradiotherapy was administered at 40 or 45 Gy in 20-25 fractions with concurrent oral UFT (tegafur/uracil; 400 mg/m2) or S-1 (tegafur/gimeracil/oteracil; 80 mg/m2). ...
Chemoradiotherapy was administered at 40 or 45 Gy in 20-25 fractions with concurrent oral UFT (tegafur/uracil; 400 mg/m …
A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non-small cell lung cancer (JCOG 0707).
Kunitoh H, Tsuboi M, Wakabayashi M, Okada M, Suzuki K, Watanabe SI, Asamura H; Japan Clinical Oncology Group Lung Cancer Surgical Study Group (JCOG-LCSSG). Kunitoh H, et al. JTCVS Open. 2020 Aug 29;4:90-102. doi: 10.1016/j.xjon.2020.08.009. eCollection 2020 Dec. JTCVS Open. 2020. PMID: 36004301 Free PMC article.
OBJECTIVE: To evaluate efficacy of S-1 (tegafur/gimeracil/oteracil), an active novel fluoropyrimidine, as compared to UFT (tegafur/uracil) as a postoperative adjuvant therapy in patients with node-negative non-small cell lung cancer (NSCLC). ...
OBJECTIVE: To evaluate efficacy of S-1 (tegafur/gimeracil/oteracil), an active novel fluoropyrimidine, as compared to UFT (tegafur …
23 results